KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Change in Receivables (2016 - 2025)

Edwards Lifesciences has reported Change in Receivables over the past 17 years, most recently at -$32.4 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$32.4 million for Q4 2025, up 69.41% from a year ago — trailing twelve months through Dec 2025 was $23.0 million (up 118.98% YoY), and the annual figure for FY2025 was $23.0 million, up 118.98%.
  • Change in Receivables for Q4 2025 was -$32.4 million at Edwards Lifesciences, down from -$13.2 million in the prior quarter.
  • Over the last five years, Change in Receivables for EW hit a ceiling of $89.5 million in Q1 2021 and a floor of -$105.9 million in Q4 2024.
  • Median Change in Receivables over the past 5 years was $11.8 million (2022), compared with a mean of $10.9 million.
  • Biggest five-year swings in Change in Receivables: surged 2030.95% in 2021 and later tumbled 3538.46% in 2024.
  • Edwards Lifesciences' Change in Receivables stood at -$6.8 million in 2021, then soared by 116.18% to $1.1 million in 2022, then surged by 1554.55% to $18.2 million in 2023, then plummeted by 681.87% to -$105.9 million in 2024, then skyrocketed by 69.41% to -$32.4 million in 2025.
  • The last three reported values for Change in Receivables were -$32.4 million (Q4 2025), -$13.2 million (Q3 2025), and $24.9 million (Q2 2025) per Business Quant data.